| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-04-15 |
| タイトル |
|
|
タイトル |
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Inui, Naoki
Suzuki, Takahito
Tanaka, Kazuki
Karayama, Masato
Inoue, Yusuke
Mori, Kazutaka
Yasui, Hideki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Matsuura, Shun
Nishimoto, Koji
Matsui, Takashi
Asada, Kazuhiro
Hashimoto, Dai
Fujii, Masato
Niwa, Mitsuru
Uehara, Masahiro
Matsuda, Hiroyuki
Koda, Keigo
Ikeda, Masaki
Inami, Nao
Tamiya, Yutaro
Kato, Masato
Nakano, Hideki
Mino, Yasuaki
Enomoto, Noriyuki
Suda, Takafumi
|
| 書誌情報 |
en : Journal of Clinical Oncology
巻 42,
号 23,
p. 2780-2789,
発行日 2024-06-04
|
| 出版者 |
|
|
出版者 |
Wolters Kluwer Health |
|
言語 |
en |
| 権利 |
|
|
権利情報 |
(C) 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
PURPOSE
We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy.
PATIENTS AND METHODS
Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety.
RESULTS
In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, ―1.3 to 13.9). The proportions of patients free of chemotherapyinduced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P< .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity.
CONCLUSION
The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration. |
| 注記 |
|
|
内容記述 |
令和6年 浜松医科大学優秀論文賞：最優秀論文賞
受賞者：乾 直輝 |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0732-183X |
| EISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1527-7755 |
| NII書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10638385 |
| PubMed番号 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
38833659 |
| 出版社DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1200/JCO.24.00278 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
JCO-42-2780.pdf (977 KB)
.png)
